JABEZ BIOSCIENCES INC.
A New Era of Small Molecules for Cancer
At Jabez, we believe the future of cancer care lies in strategic combinations, and in the fight against cancer, the mightiest allies sometimes come in small [molecule] packages.
About Jabez
At Jabez Biosciences, we’ve assembled a diverse team of industry veterans, all united by a singular mission: to develop best-in-class small molecule therapeutics that revolutionize cancer treatment. To do this, we are advancing potent, safe, and clinically efficient therapeutic compounds designed to synergize with current treatment modalities. We’re not just developing drugs, we’re engineering the future of combination cancer therapy.
Welcome to
The Future of Cancer Therapy
It is becoming clear that the future of cancer therapy lies in strategic combinations. Our small molecule DHODH inhibitor, JBZ-001, shows remarkable synergy with various therapeutic regimens including immunotherapy and chemotherapy. By shutting down cancer’s vital supply chain of nucleotides, JBZ-001 promises to revolutionize patient outcomes in a highly precise, safe, and efficient manner.
How Did We Get Here?
DHODH has been on scientists’ radar as an important driver of cancer progression since the 1950s. Initial interest waned but in the intervening decades, a series of scientific breakthroughs has rekindled scientists’ interest in this classic therapeutic target. Let’s investigate the history of this field and explore the technological and scientific breakthroughs that brought us here.
Our Pipeline
We are actively pursuing clinical investigations in various solid tumor indications and non-Hodgkin lymphoma (NHL), reflecting our commitment to addressing a broad spectrum of oncological needs. Explore our pipeline to see our current and future plans.
Useful Links
News & Media
Stay up to date on our latest news, events, and presentations. Visit our media center to get all the updates.
Investors
We’re actively seeking funding to fuel the advancement of our clinical trials. Click the link below to become a contributing member of the Jabez team
Contact
Looking to get in direct contact with out team? Click the link below to send us a message.
Our Product Roadmap
Charting the course for our DHODH inhibitor, JBZ-001
Phase I Readiness
Our DHODH inhibitor, JBZ-001, is Phase I ready with comprehensive pre-clinical data supporting its therapeutic potential
IND Filing
We filed an Investigational New Drug (IND) application to the FDA, marking a significant milestone in our development process.
Study Start
The clinical study is expected to commence, bringing us closer to offering a new treatment option for cancer patients
First-Line Treatment Potential
JBZ-001 is anticipated to be a first-line treatment for various tumor types, with potential FDA Fast-Track designation and priority review status.
FDA Review
We aim to achieve FDA Fast-Track designation, priority review, and Orphan-Drug status for JBZ-001, expediting the review process.
Market Launch
Following successful trials and regulatory approvals, we plan to launch JBZ-001, providing new hope for cancer patients worldwide.